Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 301.6% from a year ago
Total equity stood at $5.27M at the end of Q1 FY2026, up 301.6% from a year earlier and up 194.4% from the prior quarter. Over 3 fiscal years it compounded at -48.6% a year.
Context
- Total equity amounted to 50.2% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +301.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 1.79M USD
- Year-over-year change
- -29.3%
- 4-year CAGR
- -49.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.79M | -29.3% |
| FY2024 | 2024-12-31 | 2.53M | -62.2% |
| FY2023 | 2023-12-31 | 6.7M | -49.3% |
| FY2022 | 2022-12-31 | 13.21M | -50.8% |
| FY2021 | 2021-12-31 | 26.83M | — |
Total Equity vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +301.6% is the 2nd highest of 9, against a peer median of +3.5%.
- Total equity amounts to 50.2% of total assets for GLSI, versus a peer median of 85.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $241.48M USD | -22.4% | -16.6% | 88.7% | |
| Mar 2026 | $84.36M USD | +779.4% | +92.4% | 88.0% | |
| Mar 2026 | $29.91M USD | +143.8% | -5.2% | 82.8% | |
| Mar 2026 | $23.19M USD | +135.3% | +19.4% | 78.1% | |
| Mar 2026 | $5.27M USD | +301.6% | -48.6% | 50.2% | |
| Mar 2026 | -CA$5.13M CAD | -179.0% | — | 62.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$45.84M USD | -1003.5% | -30.8% | 68.6% |
| Mar 2026 | -$227.98M USD | +29.3% | — | 122.3% | |
| Mar 2026 | -$278.15M USD | -5002.1% | — | 230.4% | |
| Peer median (excluding GLSI) | — | +3.5% | -5.2% | 85.4% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.